PMC/PubMed Indexed Articles
Indexed In
- Academic Journals Database
- Open J Gate
- Genamics JournalSeek
- JournalTOCs
- China National Knowledge Infrastructure (CNKI)
- Scimago
- Ulrich's Periodicals Directory
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- MIAR
- University Grants Commission
- Geneva Foundation for Medical Education and Research
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Virus like particle (VLP) forming DNA vaccine Encapsidated in Nonreplicable Baculovirus Nanocarrier
5th Asia Pacific Global Summit and Expo on Vaccines & Vaccination
July 27-29, 2015 Brisbane, Australia
Yongdae Gwon and Young Bong Kim
Posters-Accepted Abstracts: J Vaccines Vaccin
Abstract:
Despite the advantages of DNA vaccines, overcoming their lower efficacy relative to that of conventional vaccines remains a challenge. Here, we constructed a human endogenous retrovirus (HERV) envelope-coated, nonreplicable, baculovirusbased virus like particle (VLP) forming DNA vaccine against swine influenza A/California/04/2009(H1N1). Previous we reported the efficacy of influenza HA DNA vaccine using a non-replicable baculoviral DNA vaccine (AcHERV-pdmH1N1 HA). However, AcHERV-pdmH1N1 HA vaccine only elicits an immune response against same HA antigen and limits the degree of immune response against whole viral antigen compare to the commercial killed vaccine. Here, we constructed a baculovirus carrying pdmH1N1 HA, NA and M gene for making VLP in host cell. Comparable to monovalent HA vaccine, AcHERVpdmH1N1 HA-NA-M showed a strong humoral, cellular immune responses, and protected against pathogenic H1N1 virus in challenge test. Our AcHERV-pdmH1N1 VLP forming DNA vaccine could be a potential vaccine candidate to achieve an efficacy comparable to that of killed virus vaccines.